Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.

Breul J, Lundström E, Purcea D, Venetz WP, Cabri P, Dutailly P, Goldfischer ER

Advances in therapy27 Dec 2016Cited by 15 (Europe PMC)

PMID28028737PMCIDPMC5331090DOI10.1007/s12325-016-0466-7PepBankPUB-28028737

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanObservational studyEfficacy outcome
In men with prostate cancer, triptorelin achieved testosterone below 20 ng/dl in 79%, 92%, 93%, 90%, and 91% at successive assessments.
In plain wordsIn men with prostate cancer, most triptorelin recipients reached testosterone below the study threshold.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTestosterone below 20 ng/dl over time
Study
n = 920
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2-12 monthsAs given in this study (human).
Measurements
Success rate
79%
1 month
Success rate
92%
3 months
Success rate
93%
6 months
Success rate
90%
9 months
Success rate
91%
12 months
Source sentences
Summary
After 1, 3, 6, 9, and 12 months of treatment, 79%, 92%, 93%, 90%, and 91% of patients reached testosterone levels <20 ng/dl, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.
Summary · context
Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Summary · context
Patients were treated with triptorelin SR formulations for 2-12 months.
Report a problemFND-2802873701
02HumanObservational studyEfficacy outcome
In men with prostate cancer, the monthly triptorelin formulation achieved testosterone suppression success rates of 80-92%.
In plain wordsIn men with prostate cancer, the monthly triptorelin formulation reached the testosterone target in most patients.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTestosterone suppression success with monthly formulation
Study
n: not reported in source
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2-12 monthsAs given in this study (human).
Measurements
Success rate
80 to 92%
1-month formulation
Source sentences
Summary
For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone values of 2.9 (2.9-6.5), 5.0 (2.9-8.7), and 8.7 (5.8-14.1) ng/dl at study end, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.
Summary · context
Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Summary · context
Patients were treated with triptorelin SR formulations for 2-12 months.
Report a problemFND-2802873702
03HumanObservational studyEfficacy outcome
In men with prostate cancer, the three-month triptorelin formulation achieved success rates of 83-93%.
In plain wordsIn men with prostate cancer, the three-month triptorelin formulation reached the testosterone target in most patients.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTestosterone suppression success with three-month formulation
Study
n: not reported in source
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2-12 monthsAs given in this study (human).
Measurements
Success rate
83 to 93%
3-month formulation
Source sentences
Summary
For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone values of 2.9 (2.9-6.5), 5.0 (2.9-8.7), and 8.7 (5.8-14.1) ng/dl at study end, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.
Summary · context
Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Summary · context
Patients were treated with triptorelin SR formulations for 2-12 months.
Report a problemFND-2802873703
04HumanObservational studyEfficacy outcome
In men with prostate cancer, the six-month triptorelin formulation achieved success rates of 65-97%.
In plain wordsIn men with prostate cancer, the six-month triptorelin formulation reached the testosterone target in most patients.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableTestosterone suppression success with six-month formulation
Study
n: not reported in source
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2-12 monthsAs given in this study (human).
Measurements
Success rate
65 to 97%
6-month formulation
Source sentences
Summary
For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone values of 2.9 (2.9-6.5), 5.0 (2.9-8.7), and 8.7 (5.8-14.1) ng/dl at study end, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.
Summary · context
Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Summary · context
Patients were treated with triptorelin SR formulations for 2-12 months.
Report a problemFND-2802873704
05HumanObservational studyEfficacy outcome
In men with prostate cancer, median study-end testosterone was 2.9 ng/dl with monthly triptorelin.
In plain wordsIn men with prostate cancer, monthly triptorelin produced a low median testosterone level at study end.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStudy-end testosterone with monthly formulation
Study
n: not reported in source
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2-12 monthsAs given in this study (human).
Measurements
Median testosterone
2.9 ng/dl
1-month formulation
Testosterone interquartile range
2.9 to 6.5 ng/dl
1-month formulation
Source sentences
Summary
For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone values of 2.9 (2.9-6.5), 5.0 (2.9-8.7), and 8.7 (5.8-14.1) ng/dl at study end, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.
Summary · context
Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Summary · context
Patients were treated with triptorelin SR formulations for 2-12 months.
Report a problemFND-2802873705
06HumanObservational studyEfficacy outcome
In men with prostate cancer, median study-end testosterone was 5.0 ng/dl with the three-month triptorelin formulation.
In plain wordsIn men with prostate cancer, the three-month triptorelin formulation produced a low median testosterone level at study end.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStudy-end testosterone with three-month formulation
Study
n: not reported in source
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2-12 monthsAs given in this study (human).
Measurements
Median testosterone
5 ng/dl
3-month formulation
Testosterone interquartile range
2.9 to 8.7 ng/dl
3-month formulation
Source sentences
Summary
For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone values of 2.9 (2.9-6.5), 5.0 (2.9-8.7), and 8.7 (5.8-14.1) ng/dl at study end, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.
Summary · context
Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Summary · context
Patients were treated with triptorelin SR formulations for 2-12 months.
Report a problemFND-2802873706
07HumanObservational studyEfficacy outcome
In men with prostate cancer, median study-end testosterone was 8.7 ng/dl with the six-month triptorelin formulation.
In plain wordsIn men with prostate cancer, the six-month triptorelin formulation produced a low median testosterone level at study end.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableStudy-end testosterone with six-month formulation
Study
n: not reported in source
Analysis
Primary
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
Dose not stated · 2-12 monthsAs given in this study (human).
Measurements
Median testosterone
8.7 ng/dl
6-month formulation
Testosterone interquartile range
5.8 to 14.1 ng/dl
6-month formulation
Source sentences
Summary
For the 1-, 3-, and 6-month formulations success rates ranged from 80-92%, from 83-93%, and from 65-97% with median (interquartile range) serum testosterone values of 2.9 (2.9-6.5), 5.0 (2.9-8.7), and 8.7 (5.8-14.1) ng/dl at study end, respectively.
3 context sentences(design, population, supporting numbers)
Summary · context
Therefore, we undertook a pooled retrospective analysis on the efficacy of 1-, 3-, and 6-month sustained-release (SR) formulations of the gonadotropin-releasing hormone (GnRH) agonist triptorelin to suppress serum testosterone concentrations beyond current standards.
Summary · context
Data of 920 male patients with PC enrolled in 9 prospective studies using testosterone serum concentrations as primary endpoint were pooled.
Summary · context
Patients were treated with triptorelin SR formulations for 2-12 months.
Report a problemFND-2802873707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Efficacy of Testosterone Suppression with Sustained-Release Triptorelin in Advanced Prostate Cancer.

Summary

Results from this study7

Version history

Subjects

Publication types

MeSH terms

Keywords